Claims

- 1. An oligomer-polymer composition, consisting of a combination of at least two biologically degradable inert materials and at least one biologically active ingredient.
- 2. The oligomer-polymer composition of claim 1, wherein the biologically degradable inert materials are polymerization products of identical or different hydroxycarboxylic acids.
- 3. The oligomer-polymer composition of claim 2, wherein the hydroxycarboxylic acids are lactic acid of glycolic acid.
- 4. The oligomer-polymer composition of one of the preceding claims, wherein at least one of the biologically degradable inert materials is a liquid, low molecular weight oligomer and the other a solid, higher molecular weight polymer.
- 5. The oligomer-polymer composition of claim 4, wherein the liquid, low molecular weight oligomer is a compound of the general Formula I, II or III

wherein

R is the same or different for the variables m, n,\o, p, q and r and represents $-CH_2$ -, $-CH(CH_3)$ -, $-(CH_2)_5$ -, $-CH_2$ - $-CH_2$ -O- $-CH_2$ -, $-CH_2$ - $-CH_2$ -O- $-CH_2$ -O-

 R_1 represents $-CH_2$ -COOY, $-CH(CH_3)$ -COOY, $-CH_2$ - CH_2 -COOY, $-CH_2$ - CH_2 -COOY, $-CH_2$ - CH_2 -CH $_2$ -COOY, $-CH_2$ - CH_2 -CH $_2$ -COOY, $-CH_2$ - CH_2 -CH $_2$ -COOY, $-CH_2$ -CH $_2$ -CH $_2$ -COOY, $-CH_2$ -COOY, $-CH_2$ -CH $_2$ -COOY, $-CH_2$ -

R₂ represents -CH₂-CH(CH₃)-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-CH₂-, -CH₂-CH₂-, -CH₂-CH₂-, -CH₂-CH₂-, -CH₂-CH₂-, -(CH₂)₂-O-(CH₂)₂-O-(CH₂)₂-O-(CH₂)₂-O-(CH₂)₂-O-(CH₂)₂-O-(CH₂)₂-O-(CH₂)₂-O-(CH₂)₂-, -CH₂-CH(-Y)-CH₂-, cyclohexane-1,2-diyl, cyclohexane-1,3-diyl or cyclohexane-1,4-diyl,

 R_3 represents $(-CH_2)_2CH$ -, $(-CH_2)_3$ - CH_3 or $(-CH_2)_3C$ - CH_2 - CH_3 ,

Y being -H, -CN₃, C_2H_5 , - C_3H_7 or - C_4H_9 and

m, n, o, p, q and r independently of one another being a whole number from 2 to 18.

- 6. The oligomer-polymer composition of claim 5, wherein R is $-CH(CH_3)$ -, R_1 is $-CH(CH_3)$ -COOY, Y is $-C_2H_5$ and m, n, o, p, q or r is a whole number from 2 to 4.
- 7. The oligomer-polymer composition of claim 4, wherein the liquid low molecular weight oligomer is selected from the following group or from mixtures of this group, namely poly(hydroxyesters), such as poly-(L-lactides), poly-(D,L-lactides), polyglycolides, poly-(caprolactones), poly(dioxanones), poly-(hydroxybutyric acids), poly-(hydroxyvaleric acids), poly-(glycosalicylates) and copolymers of these compounds, poly-(hydroxy esters), which are synthesized by a ring opening polymerization of lactones in the presence of a biocompatible starter molecule, namely, L-lactide, D,L-lactide, glycolide, p-dioxanone and e-caprolactone, with aliphatic or cycloaliphatic compounds with one or more free hydroxyl groups, such as alkyl L-lactate, cholesterol, 1,2-dihydroxypropane, triethylene glycol, glycerol or pentaerythritol as biocompatible starter molecules.

- 8. The oligomer-polymer composition of one of the claims 4 to 7, wherein the ratio of solid, higher molecular weight polymer to liquid, lower molecular weight oligomer is 1:100 to 1:1 and preferably 1:10 to 1:2.
- 9. The oligomer-polymer composition of one of the preceding claims, wherein the biologically active ingredient is selected from the group comprising hormones, immune modulators, immune suppressive agents, antibiotics, cytostatic agents, diuretics, gastrointestinal drugs, cardiovascular drugs and neuropharmacological drugs.
- 10. The oligomer-polymer composition of claim 9, wherein the biologically active ingredient is present in the composition of inactive ingredient in dissolved or suspended form.
- 11. The oligomer-polymer composition of one of the preceding claims, wherein this composition is present in the form of an injectable material, which, when injected, forms a coagulate under the influence of body fluid.
- 12. An injectable implant, obtainable by injecting an oligomer-polymer composition of claim 1 into a body.
- 13. A method for preparing an injectable implant, wherein an oligomer-polymer composition of claim 1 is injected into the body of a mammal.

add 36